These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 27074969)

  • 1. Opposite activation of the Hedgehog pathway in CD138+ plasma cells and CD138-CD19+ B cells identifies two subgroups of patients with multiple myeloma and different prognosis.
    Martello M; Remondini D; Borsi E; Santacroce B; Procacci M; Pezzi A; Dico FA; Martinelli G; Zamagni E; Tacchetti P; Pantani L; Testoni N; Marzocchi G; Rocchi S; Zannetti BA; Mancuso K; Cavo M; Terragna C
    Leukemia; 2016 Sep; 30(9):1869-76. PubMed ID: 27074969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD138-negative clonogenic cells are plasma cells but not B cells in some multiple myeloma patients.
    Hosen N; Matsuoka Y; Kishida S; Nakata J; Mizutani Y; Hasegawa K; Mugitani A; Ichihara H; Aoyama Y; Nishida S; Tsuboi A; Fujiki F; Tatsumi N; Nakajima H; Hino M; Kimura T; Yata K; Abe M; Oka Y; Oji Y; Kumanogoh A; Sugiyama H
    Leukemia; 2012 Sep; 26(9):2135-41. PubMed ID: 22430638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD19-CD45 low/- CD38 high/CD138+ plasma cells enrich for human tumorigenic myeloma cells.
    Kim D; Park CY; Medeiros BC; Weissman IL
    Leukemia; 2012 Dec; 26(12):2530-7. PubMed ID: 22733078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma.
    Blotta S; Jakubikova J; Calimeri T; Roccaro AM; Amodio N; Azab AK; Foresta U; Mitsiades CS; Rossi M; Todoerti K; Molica S; Morabito F; Neri A; Tagliaferri P; Tassone P; Anderson KC; Munshi NC
    Blood; 2012 Dec; 120(25):5002-13. PubMed ID: 22821765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A critical role of autocrine sonic hedgehog signaling in human CD138+ myeloma cell survival and drug resistance.
    Liu Z; Xu J; He J; Zheng Y; Li H; Lu Y; Qian J; Lin P; Weber DM; Yang J; Yi Q
    Blood; 2014 Sep; 124(13):2061-71. PubMed ID: 25049282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma.
    Peacock CD; Wang Q; Gesell GS; Corcoran-Schwartz IM; Jones E; Kim J; Devereux WL; Rhodes JT; Huff CA; Beachy PA; Watkins DN; Matsui W
    Proc Natl Acad Sci U S A; 2007 Mar; 104(10):4048-53. PubMed ID: 17360475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phenotypic, genomic and functional characterization reveals no differences between CD138++ and CD138low subpopulations in multiple myeloma cell lines.
    Paíno T; Sarasquete ME; Paiva B; Krzeminski P; San-Segundo L; Corchete LA; Redondo A; Garayoa M; García-Sanz R; Gutiérrez NC; Ocio EM; San-Miguel JF
    PLoS One; 2014; 9(3):e92378. PubMed ID: 24658332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Expression and clinical significance of Notch1 on the membrane of bone marrow CD38(+)CD138(+) plasma cells in the patients with multiple myeloma].
    Zhao YR; Fu R; Guan J; Gao S; Liu H; Ruan EB; Qu W; Liang Y; Wang GJ; Wang XM; Liu H; Wu YH; Song J; Wang HQ; Xing LM; Wang J; Li LJ; Shao ZH
    Zhonghua Xue Ye Xue Za Zhi; 2012 Apr; 33(4):274-7. PubMed ID: 22781716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leukemic B cells clonally identical to myeloma plasma cells are myelomagenic in NOD/SCID mice.
    Pilarski LM; Seeberger K; Coupland RW; Eshpeter A; Keats JJ; Taylor BJ; Belch AR
    Exp Hematol; 2002 Mar; 30(3):221-8. PubMed ID: 11882359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-primed natural killer cells from patients with multiple myeloma lyse autologous, NK-resistant, bone marrow-derived malignant plasma cells.
    Katodritou E; Terpos E; North J; Kottaridis P; Verrou E; Gastari V; Chadjiaggelidou C; Sivakumaran S; Jide-Banwo S; Tsirogianni M; Kapetanos D; Zervas K; Lowdell MW
    Am J Hematol; 2011 Dec; 86(12):967-73. PubMed ID: 21919039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RARα2 expression confers myeloma stem cell features.
    Yang Y; Shi J; Tolomelli G; Xu H; Xia J; Wang H; Zhou W; Zhou Y; Das S; Gu Z; Levasseur D; Zhan F; Tricot G
    Blood; 2013 Aug; 122(8):1437-47. PubMed ID: 23847194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversible expression of CD138 on mature follicular B cells is downregulated by IL-4.
    Lee JG; Moon H; Park C; Shin SH; Kang K; Kim TJ
    Immunol Lett; 2013; 156(1-2):38-45. PubMed ID: 24029663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flow cytometric evaluation of bone marrow plasma cells using CD19, CD45, CD56, CD38, and CD138 and correlation with bone marrow infiltration ratio in multiple myeloma patients.
    Kara IO; Sahin B; Paydas S; Cetiner S
    Saudi Med J; 2004 Nov; 25(11):1587-92. PubMed ID: 15573184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The evaluation of minimal residual disease in multiple myeloma by fluorescent molecular beacons in real time PCR of IgH gene rearrangements and correlation with flow cytometry.
    Kara IO; Duman BB; Afsar CU
    J BUON; 2013; 18(2):442-7. PubMed ID: 23818359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A subpopulation of malignant CD34+CD138+B7-H1+ plasma cells is present in multiple myeloma patients.
    Kuranda K; Berthon C; Dupont C; Wolowiec D; Leleu X; Polakowska R; Jouy N; Quesnel B
    Exp Hematol; 2010 Feb; 38(2):124-31. PubMed ID: 19948206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple myeloma-initiating cells.
    Hosen N
    Int J Hematol; 2013 Mar; 97(3):306-12. PubMed ID: 23420183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of bone marrow plasma cell infiltrates in multiple myeloma: the added value of CD138 immunohistochemistry.
    Al-Quran SZ; Yang L; Magill JM; Braylan RC; Douglas-Nikitin VK
    Hum Pathol; 2007 Dec; 38(12):1779-87. PubMed ID: 17714757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of clonogenic multiple myeloma cells.
    Matsui W; Huff CA; Wang Q; Malehorn MT; Barber J; Tanhehco Y; Smith BD; Civin CI; Jones RJ
    Blood; 2004 Mar; 103(6):2332-6. PubMed ID: 14630803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mucosal plasma cell barrier disruption during intestine transplant rejection.
    Ningappa M; Ashokkumar C; Ranganathan S; Schmitt L; Higgs BW; Sun Q; Branca M; Mazariegos G; Zeevi A; Abu-Elmagd K; Squires R; Rudolph J; Alissa F; Hakonarson H; Sindhi R
    Transplantation; 2012 Dec; 94(12):1236-42. PubMed ID: 23269450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The phenotypic plasticity of myeloma plasma cells as expressed by dedifferentiation into an immature, resilient, and apoptosis-resistant phenotype.
    Yaccoby S
    Clin Cancer Res; 2005 Nov; 11(21):7599-606. PubMed ID: 16278377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.